Lupus Anticoagulant
Lupus Anticoagulant
Lupus Anticoagulant
ANTICOAGULANT
GROUP 1 BSMT 3D
PANIZA, ERIKA JOY M.
VILLANUEVA, ANDREW ARNOLD D.
YANDAN, CHARIS M.
Lupus Anticoagulant
• LA, LAC, Lupus antibody, Lupus inhibitor
• Misnomer->Prothrombotic and Anticoagulant
• aPL
• In Vivo: Procoagulant In Vitro: Anticoagulant
Antiphospholipids
• aPL
• Binding ability with membrane proteins
• Comprises of:
-LA
-Anticardiolipin(ACL)
-Beta 2 Glycoprotein I(B-2GPI)
Etiology
• Antigen-driven immune response
• Autoimmunity
• Unknown inciting antigen and genetic cause
• Occurs in disease states
Epidemiology
• Misnomer
• 1-2% of the population(aPL)
• 30-40% of SLE patients
Pathophysiology
• Phospholipids:
-cell membrane lipids
-ampiphilic (lipid bilayer)
-two fatty acid tails and a phosphate head
In Vivo:
• Human Monocyte Procoagulant Activity(Schved et. al)
• LA enhances monocyte induced TNF-a activity
• TNF-a->upregulation of tissue factor->DIC
• Role of Platelets (Sletnes):
- tenase and prothrombinase complex
-anionic phospholipids and microvesicles shedding
In Vitro:
• Phospholipid dependency of coagulation(Celli et. al)
• LA interferes with PDC pathway->prolongs coagulation
• LA binds to exposed phospholipid layer
• Antiphospholipid Syndrome
Laboratory Diagnosis and Findings
1. Complete Blood Count
2. Bleeding Time
3. Clotting Time
4. Activated Partial Thromboplastin Test
5. Prothrombin time
6. Thrombin/Reptilase Time Test
7. Fibrinogen Test
8. Russell Viper Venom Time
9. Factor VIII levels
Laboratory Test Results of Patients with Lupus Anticoagulant
TESTS RESULTS